Table 1.

Serum levels of autoantibodies of BALB/c recipients on day 15 after donor-cell injection


Donor cells, 50 × 106

Total IgG1, μg/mL

Total IgG2a, μg/mL

Anti-dsDNA IgG1, U/mL

Anti-dsDNA IgG2a, U/mL

Anti-dsDNA IgG2aa, U/mL
DBA/2 whole SPL   1157 ± 58   4033 ± 279   3162 ± 603   1459 ± 163   <10  
DBA/2 CD4--SPL   484 ± 41   731 ± 60   407 ± 43   335 ± 41   <10  
DBA/2 CD8--SPL   1953 ± 204   5051 ± 729   2630 ± 276   1073 ± 481   <10  
DBA/2 B220--SPL   346 ± 43   455 ± 42   225 ± 46   140 ± 16   <10  
No injection   97 ± 5   43 ± 4.2   <10   <10   <10  
NZB SPL*
 
NA
 
NA
 
NA
 
366 ± 79
 
293 ± 32
 

Donor cells, 50 × 106

Total IgG1, μg/mL

Total IgG2a, μg/mL

Anti-dsDNA IgG1, U/mL

Anti-dsDNA IgG2a, U/mL

Anti-dsDNA IgG2aa, U/mL
DBA/2 whole SPL   1157 ± 58   4033 ± 279   3162 ± 603   1459 ± 163   <10  
DBA/2 CD4--SPL   484 ± 41   731 ± 60   407 ± 43   335 ± 41   <10  
DBA/2 CD8--SPL   1953 ± 204   5051 ± 729   2630 ± 276   1073 ± 481   <10  
DBA/2 B220--SPL   346 ± 43   455 ± 42   225 ± 46   140 ± 16   <10  
No injection   97 ± 5   43 ± 4.2   <10   <10   <10  
NZB SPL*
 
NA
 
NA
 
NA
 
366 ± 79
 
293 ± 32
 

Data are presented as means ± SE; n = 10.

CD4--SPL indicates CD4+ T cell–depleted spleen cells; CD8--SPL, CD8+ T cell–depleted spleen cells; B220--SPL, B220+ B cell–depleted spleen cells; and NA, not applicable.

*

IgG2a antibodies secreted by B cells from NZB mice are allotype a, and serum of BALB/c recipients given donor NZB spleen cells was used as positive control for anti-dsDNA IgG2aa

Close Modal

or Create an Account

Close Modal
Close Modal